Verona Pharma plc is a UK-based biopharmaceutical company focused on developing and commercializing therapies for chronic respiratory diseases.
Its lead product, ensifentrine (Ohtuvayre), is an inhaled, selective dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor approved in 2024 in the United States for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The molecule provides both bronchodilator and non-steroidal anti-inflammatory effects and is being evaluated for additional respiratory indications, including non-cystic fibrosis bronchiectasis.
